Skip to content
Prednicarbate
Dermatop (prednicarbate) is a small molecule pharmaceutical. Prednicarbate was first approved as Dermatop on 1991-09-23. It is used to treat facial dermatoses, foot dermatoses, hand dermatoses, inflammation, and leg dermatoses amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Prednicarbate
Tradename
Company
Number
Date
Products
DERMATOP E EMOLLIENTBausch Health CompaniesN-020279 DISCN1993-10-29
1 products, RLD
DERMATOPBausch Health CompaniesN-019568 DISCN1991-09-23
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
prednicarbateANDA2018-04-12
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
facial dermatoses—D005148—
foot dermatoses—D005533—
hand dermatoses—D006229—
inflammationMP_0001845D007249—
leg dermatoses—D007868—
pruritusHP_0000989D011537L29
scalp dermatoses—D012536—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D07: Corticosteroids, dermatological preparations
— D07A: Corticosteroid dermatological preparations, plain
— D07AC: Corticosteroids, potent (group iii)
— D07AC18: Prednicarbate
HCPCS
No data
Clinical
Clinical Trials
36 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
T-cell lymphoma peripheralD016411C84.94641113
Disease progressionD018450———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
T-cell lymphomaD016399111——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-hodgkin lymphomaD008228C85.932———3
Multiple myelomaD009101C90.021———2
AdenocarcinomaD000230—2———2
Squamous cell carcinomaD002294—2———2
Non-small-cell lung carcinomaD00228911———2
Large-cell lymphoma anaplasticD017728C84.612———2
Mycosis fungoidesD009182C84.021———2
B-cell lymphomaD01639312———2
Hodgkin diseaseD006689C8122———2
LymphomaD008223C85.922———2
Show 15 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C803————3
T-cell lymphoma cutaneousD016410C84.A2————2
Sezary syndromeD012751C84.11————1
Primary cutaneous anaplastic large cell lymphomaD054446C86.61————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePREDNICARBATE
INNprednicarbate
Description
Prednicarbate is a corticosteroid hormone.
Classification
Small molecule
Drug classprednisone and prednisolone derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCOC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Identifiers
PDB—
CAS-ID73771-04-7
RxCUI34369
ChEMBL IDCHEMBL1200386
ChEBI ID—
PubChem CID6714002
DrugBankDB01130
UNII IDV901LV1K7D (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 185 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
537 adverse events reported
View more details